Samir Kumar Patra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Samir Kumar Patra has a total of 158 co-authors. Here are the top co-authors by number of shared publications:
Moonmoon Deb
23 shared publications- Dipta Sengupta
MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh
21 shared publications Ankan Roy
Epigenetics and Cancer Research Laboratory, Biochemistry and Molecular Biology Group, Department of Life Science, National Institute of Technology, Rourkela, Odisha, 769008, India; ICMR Collaborating Centre of Excellence (ICMR-CCoE), Department of Life Science, National Institute of Technology, Rourkela, Odisha, 769008, India
20 shared publicationsSwayamsiddha Kar
Epigenetics and Cancer Research Laboratory, Biochemistry and Molecular Biology Group, Department of Life Science, National Institute of Technology, Rourkela, India
20 shared publicationsSabnam Parbin
17 shared publicationsNibedita Pradhan
Epigenetics and Cancer Research Laboratory, Biochemistry and Molecular Biology Group, Department of Life Science, National Institute of Technology, Rourkela, Odisha, 769008, India
13 shared publications
Latest Publications
- Open Access
- 12 October 2026
- Published by Springer Nature in Diabetes Therapy
- p. 1-32
The Bidirectional Relationship Between Diabetes and Cancer: Mechanistic Insights, Epigenetic Intermediaries, and Therapeutic Approaches
- 12 October 2026
- Published by Springer Nature in Diabetes Therapy
- p. 1-32
Open AccessThe Bidirectional Relationship Between Diabetes and Cancer: Mechanistic Insights, Epigenetic Intermediaries, and Therapeutic Approaches
- 19 September 2026
- Published by Springer Nature in British Journal of Cancer
- p. 1-18
PAX9 activates autophagy through a transcription-dependent mechanism, promoting EGFR degradation to restrict cell survival in oral cancer
Background PAX9 (paired box 9) gene, a transcription factor belonging to the PAX family, is associated with craniofacial development. Dysregulation of PAX9 is associated with oral squamous cell carcinoma (OSCC), and its functional regulation in OSCC remains unknown. Methods PAX9 expression was evaluated in human OSCC tissues and a DMBA-induced hamster oral carcinogenesis model, and its functional role in cell death and autophagy was assessed using PAX9 overexpression and PAX9 mutants in OSCC. Autophagy, lysosomal activity, apoptosis, EGFR degradation, and chemosensitivity were analysed in vitro and in an OSCC xenograft model. Results Overexpression of PAX9 activated autophagy and enhanced lysosomal function through a transcription-dependent mechanism, thereby inducing apoptosis in OSCC. Mutations at L27P and I29T in PAX9 blocked autophagy and restored cell viability in OSCC. Interestingly, PAX9 was shown to activate lethal autophagy, which degrades EGFR, thereby inducing cell death and chemosensitisation in OSCC. Moreover, PAX9 expression decreased in higher-grade human oral cancers and in DMBA-induced hamster oral carcinogenesis, and in vitro exposure to carcinogens reduced PAX9 while increasing DNMT1, suggesting that DNA methylation may regulate PAX9 during oral carcinogenesis. Conclusion PAX9 activates lethal autophagy, promoting EGFR degradation and apoptosis in OSCC, highlighting its tumour-suppressive potential and therapeutic relevance.
- 19 September 2026
- Published by Springer Nature in British Journal of Cancer
- p. 1-18
PAX9 activates autophagy through a transcription-dependent mechanism, promoting EGFR degradation to restrict cell survival in oral cancer
Background PAX9 (paired box 9) gene, a transcription factor belonging to the PAX family, is associated with craniofacial development. Dysregulation of PAX9 is associated with oral squamous cell carcinoma (OSCC), and its functional regulation in OSCC remains unknown. Methods PAX9 expression was evaluated in human OSCC tissues and a DMBA-induced hamster oral carcinogenesis model, and its functional role in cell death and autophagy was assessed using PAX9 overexpression and PAX9 mutants in OSCC. Autophagy, lysosomal activity, apoptosis, EGFR degradation, and chemosensitivity were analysed in vitro and in an OSCC xenograft model. Results Overexpression of PAX9 activated autophagy and enhanced lysosomal function through a transcription-dependent mechanism, thereby inducing apoptosis in OSCC. Mutations at L27P and I29T in PAX9 blocked autophagy and restored cell viability in OSCC. Interestingly, PAX9 was shown to activate lethal autophagy, which degrades EGFR, thereby inducing cell death and chemosensitisation in OSCC. Moreover, PAX9 expression decreased in higher-grade human oral cancers and in DMBA-induced hamster oral carcinogenesis, and in vitro exposure to carcinogens reduced PAX9 while increasing DNMT1, suggesting that DNA methylation may regulate PAX9 during oral carcinogenesis. Conclusion PAX9 activates lethal autophagy, promoting EGFR degradation and apoptosis in OSCC, highlighting its tumour-suppressive potential and therapeutic relevance.
- 22 May 2026
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 44 (9) , 317-342
Epigenetic signatures and risk determinants in bladder cancer: Implications for diagnostic and therapeutic interventions
- 22 May 2026
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 44 (9) , 317-342
Epigenetic signatures and risk determinants in bladder cancer: Implications for diagnostic and therapeutic interventions
- 13 October 2025
- Published by Wiley in FEBS Letters
- Vol. 600 (1) , 63-82
KIF5A upregulation by FAK ‐mediated downregulation of epigenetic modifiers promotes mitochondrial dynamics in neuronal differentiation
Neuronal differentiation depends on mitochondrial transport and networking toward the developing axon and dendrites. Herein, we report that the motor protein kinesin family member 5A (KIF5A) is essential for neuronal maturation through regulation of mitochondrial structure and dynamics. Focal adhesion kinase (FAK) signaling promotes differentiation through enhanced expression of KIF5A and downregulation of epigenetic modifiers, DNMT1 and KDM5A. FAK activity is phosphorylation‐dependent to facilitate neuronal differentiation by KIF5A and repression of DNMT1 and KDM5A. This is the first report showing that FAK signaling controls epigenetic regulation of motor proteins by downregulation of epigenetic modifiers. Thus, molecular mechanisms for neurodevelopment and plausible therapeutic targets against neurodegenerative disorders are explored in this article.
- 13 October 2025
- Published by Wiley in FEBS Letters
- Vol. 600 (1) , 63-82
KIF5A upregulation by FAK ‐mediated downregulation of epigenetic modifiers promotes mitochondrial dynamics in neuronal differentiation
Neuronal differentiation depends on mitochondrial transport and networking toward the developing axon and dendrites. Herein, we report that the motor protein kinesin family member 5A (KIF5A) is essential for neuronal maturation through regulation of mitochondrial structure and dynamics. Focal adhesion kinase (FAK) signaling promotes differentiation through enhanced expression of KIF5A and downregulation of epigenetic modifiers, DNMT1 and KDM5A. FAK activity is phosphorylation‐dependent to facilitate neuronal differentiation by KIF5A and repression of DNMT1 and KDM5A. This is the first report showing that FAK signaling controls epigenetic regulation of motor proteins by downregulation of epigenetic modifiers. Thus, molecular mechanisms for neurodevelopment and plausible therapeutic targets against neurodegenerative disorders are explored in this article.
- Open Access
AKNA drives neural stem cell fate transition through differential localization and coordinating the modulation of chromatin from H3K27me3 to H3K27ac
Neuronal stem cells (NSCs) play pivotal role in adult neurogenesis, however, detail mechanisms of obtaining pluripotency or undergoing differentiation remain unknown. Herein, how AT-hook protein AKNA regulates pluripotency and stemness in neuroblastoma cells is demonstrated by gene knockdown, immunofluorescence, chromatin immunoprecipitation (ChIP), localization of AKNA, signaling interactions and transcriptional activity. AKNA was abundant and mostly nuclear during induction of pluripotency and its knockdown reduced stemness, even in presence of other pluripotency factors, including OCT4 and SOX2. During the course of induction of differentiation, AKNA remain localized in the cytosol, essential for regulated differentiation. Cytosolic retention of AKNA is possibly driven by FAK signaling. In the nucleus, AKNA promotes KDM6B demethylase for H3K27me3 demethylation to H3K27, and subsequently promotes CBP/p300 to acetylate H3K27 to H3K27ac deposition on promoter region of respective genes to trigger their transcription. Data obtained from knockdown and overexpression of AKNA and KDM6B further reinforce its importance that, they physically interact to drive pluripotency and stemness. These findings establish AKNA as a critical regulator for NSCs fate determination in association with epigenetic modifiers and signaling pathway, offering potential targets for neuroblastoma therapies and regenerative medicines for neurodegenerative diseases.
Open AccessAKNA drives neural stem cell fate transition through differential localization and coordinating the modulation of chromatin from H3K27me3 to H3K27ac
Neuronal stem cells (NSCs) play pivotal role in adult neurogenesis, however, detail mechanisms of obtaining pluripotency or undergoing differentiation remain unknown. Herein, how AT-hook protein AKNA regulates pluripotency and stemness in neuroblastoma cells is demonstrated by gene knockdown, immunofluorescence, chromatin immunoprecipitation (ChIP), localization of AKNA, signaling interactions and transcriptional activity. AKNA was abundant and mostly nuclear during induction of pluripotency and its knockdown reduced stemness, even in presence of other pluripotency factors, including OCT4 and SOX2. During the course of induction of differentiation, AKNA remain localized in the cytosol, essential for regulated differentiation. Cytosolic retention of AKNA is possibly driven by FAK signaling. In the nucleus, AKNA promotes KDM6B demethylase for H3K27me3 demethylation to H3K27, and subsequently promotes CBP/p300 to acetylate H3K27 to H3K27ac deposition on promoter region of respective genes to trigger their transcription. Data obtained from knockdown and overexpression of AKNA and KDM6B further reinforce its importance that, they physically interact to drive pluripotency and stemness. These findings establish AKNA as a critical regulator for NSCs fate determination in association with epigenetic modifiers and signaling pathway, offering potential targets for neuroblastoma therapies and regenerative medicines for neurodegenerative diseases.
- 16 July 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 196 (Pt B) , 110763
DNMT1 inhibition by synergistic application of curcumin and 5-AZA-2′-deoxycytidine implicates enhanced therapeutic potential against lung adenocarcinoma
- 16 July 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 196 (Pt B) , 110763
DNMT1 inhibition by synergistic application of curcumin and 5-AZA-2′-deoxycytidine implicates enhanced therapeutic potential against lung adenocarcinoma
- 9 January 2025
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1871 (3) , 167664
An epigenetic perspective of viral diseases, including cancer and autophagy
- 9 January 2025
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1871 (3) , 167664
An epigenetic perspective of viral diseases, including cancer and autophagy
- 2 December 2024
- Published by Elsevier in Cancer Genetics
- Vol. 290-291, 16-35
Screening and identification of gene expression in large cohorts of clinical tissue samples unveils the major involvement of EZH2 and SOX2 in lung cancer
- 2 December 2024
- Published by Elsevier in Cancer Genetics
- Vol. 290-291, 16-35
Screening and identification of gene expression in large cohorts of clinical tissue samples unveils the major involvement of EZH2 and SOX2 in lung cancer
- Open Access
Screening and identification of gene expression in large cohorts of clinical lung cancer samples unveils the major involvement of EZH2 and SOX2
Lung adenocarcinoma (LUAD), the primary subtype of Non-Small Cell Lung Cancer (NSCLC), accounts for 80% to 85% of cases. Due to suboptimal screening method, LUAD is often detected in late stage, leading to aggressive progression and poor outcomes. Therefore, early disease prognosis for the LUAD is high priority. In order to identify early detection biomarkers, we conducted a meta-analysis of mRNA expression TCGA and GTEx datasets from LUAD patients. A total of 795 differentially expressed genes (DEGs) were identified by exploring the Network-Analyst tool and utilizing combined effect size methods. DEGs refer to genes whose expression levels are significantly different (either higher or lower) compared to their normal baseline expression levels. KEGG pathway enrichment analysis highlighted the TNF signaling pathway as being prominently associated with these DEGs. Subsequently, using the MCODE and CytoHubba plugins in Cytoscape software, we filtered out the top 10 genes. Among these, SOX2 was the only gene exhibiting higher expression, while the others were downregulated. Consequently, our subsequent research focused on SOX2. Further transcription factor-gene network analysis revealed that enhancer of zeste homolog 2 (EZH2) is a significant partner of SOX2, potentially playing a crucial role in euchromatin-heterochromatin dynamics. Structure of SOX2 protein suggest that it is a non-druggable transcription factor, literature survey suggests the same; hence, we drove our focus to investigate on potential drug(s) targeting EZH2. Molecular docking analyses predicted most probable inhibitors of EZH2. We employed several predictive analysis tools and identified GSK343, as a promising inhibitor of EZH2.
Open AccessScreening and identification of gene expression in large cohorts of clinical lung cancer samples unveils the major involvement of EZH2 and SOX2
Lung adenocarcinoma (LUAD), the primary subtype of Non-Small Cell Lung Cancer (NSCLC), accounts for 80% to 85% of cases. Due to suboptimal screening method, LUAD is often detected in late stage, leading to aggressive progression and poor outcomes. Therefore, early disease prognosis for the LUAD is high priority. In order to identify early detection biomarkers, we conducted a meta-analysis of mRNA expression TCGA and GTEx datasets from LUAD patients. A total of 795 differentially expressed genes (DEGs) were identified by exploring the Network-Analyst tool and utilizing combined effect size methods. DEGs refer to genes whose expression levels are significantly different (either higher or lower) compared to their normal baseline expression levels. KEGG pathway enrichment analysis highlighted the TNF signaling pathway as being prominently associated with these DEGs. Subsequently, using the MCODE and CytoHubba plugins in Cytoscape software, we filtered out the top 10 genes. Among these, SOX2 was the only gene exhibiting higher expression, while the others were downregulated. Consequently, our subsequent research focused on SOX2. Further transcription factor-gene network analysis revealed that enhancer of zeste homolog 2 (EZH2) is a significant partner of SOX2, potentially playing a crucial role in euchromatin-heterochromatin dynamics. Structure of SOX2 protein suggest that it is a non-druggable transcription factor, literature survey suggests the same; hence, we drove our focus to investigate on potential drug(s) targeting EZH2. Molecular docking analyses predicted most probable inhibitors of EZH2. We employed several predictive analysis tools and identified GSK343, as a promising inhibitor of EZH2.